ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Jan 7, 2014
In-Line Is Good Enough…for Today
Valeant Pharma issues in-line guidance for 2014, while Cray reiterates outlook. Shares of both companies soar.
Jan 3, 2014
Buffett Doubles Down on USG; Teva Expected to Appoint New CEO; Crude by Rail Transportation Comes under Scrutiny
Buffett more than doubles stake in wallboard maker USG, generic pharmaceutical giant Teva rumored to find CEO, while concerns about crude-by-rail heighten.
Dec 24, 2013
The Best Ideas for 2014 and Beyond: Part I
The holiday season brings many joys with your family and friends. It also brings an outline of our favorite ideas for 2014 and beyond. We hope you enjoy the list, and we wish you and your family a very happy holiday!
Nov 22, 2013
Merger Rumors Helping Best Ideas Portfolio Holdings
Best Ideas portfolio holdings DirecTV and Teva Pharma are getting a boost thanks to the rumor mill.
Nov 1, 2013
The Curious Cases of Intuitive Surgical and Teva Pharma: What We Have Learned
Let’s talk about what we’ve learned about our process as a result of Intuitive Surgical and Teva Pharma.
Sep 23, 2013
Niaspan Generic Could Boost Teva
Teva’s generic version of Niaspan will hit the market shortly.
Aug 1, 2013
Teva Boasts a Several Billion Dollar NTE Opportunity
Revenue potential from the launch of new therapeutic entities (NTEs) in coming years should more than offset troubles from the loss of exclusivity of Copaxone.
Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015.
Aug 23, 2012
Search Dividend Reports by Company Name: Q to Z
Search dividend reports by company name: Q to Z. As a supplement to our 16-page stock reports, our dividend reports assess the safety of a firm's dividend through our Valuentum Dividend Cushion ratio, the potential growth of a firm's dividend by evaluating its capacity and willingness to increase the dividend, the historical track record of the company's dividend performance, and the overall strength of the dividend by putting all of this analysis together. Each report offers our estimate of the future growth rate of the firm's dividend.
Jun 13, 2012
Johnson and Johnson’s Deal for Synthes Closes; Healthcare Spending Will Grow
We take a look at some recent developments in the healthcare industry.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.